Scinai Files Prospectus For Resale Of Up To 2,706,450 ADS By YA II PN
https://www.sec.gov/Archives/edgar/data/1611747/000121390026103067/ea0306554-f1_scinai.htm
Stocks · News reference
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Scinai Immunotherapeutics Regains Nasdaq Compliance
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closedJERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai
Scinai Immunotherapeutics Says It Received Nasdaq Notice Confirming Regained Compliance With Minimum Bid Price Rule
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.